OBJECTIVE: Somatostatin receptor analogues are well-established in the treatment of metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs), especially for symptom control in patients with the carcinoid syndrome, and to control tumour growth. However, they need to be discontinued before peptide receptor radionuclide therapy (PRRT) as they may saturate the somatostatin receptor 2 (SSTR2) and prevent binding of the radioactive ligand. DESIGN: We evaluated the effects of the novel somatostatin analogue paltusotine on 18F-SiTATE radioligand uptake and on GEP-NET cell viability in comparison to octreotide. METHODS: Paltusotine and octreotide were evaluated in varying concentrations in an 18F-SiTATE uptake assay using stable hSSTR2 over-expressing BON-1 cells, and in a cell viability assay utilising different NET cell lines and human patient-derived GEP-NET primary cultures (n = 13). RESULTS: Low, clinically-relevant concentrations of paltusotine (7.3-25.4 nM) demonstrated no influence on cellular radioligand uptake compared to the control. In contrast, octreotide reduced radioligand uptake at low, clinically-relevant concentrations (7.3-25.4 nM) and led to a further significant reduction of radioligand uptake at higher concentrations (73-508 nM). Both paltusotine and octreotide showed overall little or no significant anti-tumour effects in vitro in NET cell lines. However, in contrast to octreotide, paltusotine led to a slight decrease in cell viability of patient-derived GEP-NET primary cultures. CONCLUSIONS: Treatment with paltusotine did not significantly reduce radioligand binding of 18F-SiTATE in vitro, indicating no influence on SSTR2 targeting. This might enable a continuation of somatostatin receptor analogue therapy with paltusotine during PRRT, potentially improving symptom control in GEP-NET patients with the carcinoid syndrome.

AKESO Prague Czech Republic

Department of Endocrinology Diabetology and Clinical Nutrition University Hospital Zurich Zurich Switzerland

Department of General Visceral and Transplantation Surgery LMU University Hospital LMU Munich Munich Germany

Department of Internal Medicine 4 LMU University Hospital LMU Munich Munich Germany

Department of Nuclear Medicine LMU University Hospital LMU Munich Munich Germany

Department of Pathology and Molecular Pathology University Hospital Zurich Zurich Switzerland

Department of Visceral and Transplantation Surgery University Hospital Zurich Zurich Switzerland

ENETS Centre of Excellence Zurich University Hospital Zurich Zurich Switzerland

Green Templeton College University of Oxford Oxford UK

Institute of Pathology Faculty of Medicine LMU Munich Munich Germany

Interdisciplinary Center of Neuroendocrine Tumors of The GastroEnteroPancreatic System LMU University Hospital Munich Germany

NET Unit ENETS Centre of Excellence Royal Free Hospital London UK

Palacky University Olomouc Czech Republic

The LOOP Zurich Medical Research Center Zurich Switzerland

Zobrazit více v PubMed

Grozinsky-Glasberg S, Davar J, Hofland J, et al. European neuroendocrine tumor society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol 2022. 34 e13146. ( 10.1111/jne.13146) PubMed DOI PMC

Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014. 371 224–233. ( 10.1056/nejmoa1316158) PubMed DOI

Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009. 27 4656–4663. ( 10.1200/jco.2009.22.8510) PubMed DOI

Pavel M, Oberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020. 31 844–860. ( 10.1016/j.annonc.2020.03.304) PubMed DOI

Hofland J, Falconi M, Christ E, et al. European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 2023. 35 e13318. ( 10.1111/jne.13318) PubMed DOI

Lamarca A, Bartsch DK, Caplin M, et al. European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol 2024. 36 e13423. ( 10.1111/jne.13423) PubMed DOI

Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013. 40 800–816. ( 10.1007/s00259-012-2330-6) PubMed DOI PMC

Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology 2017. 105 295–309. ( 10.1159/000475526) PubMed DOI

Love C, Desai NB, Abraham T, et al. ACR-ACNM-ASTRO-SNMMI practice parameter for Lutetium-177 (Lu-177) DOTATATE therapy. Am J Clin Oncol 2022. 45 233–242. ( 10.1097/coc.0000000000000903) PubMed DOI

Zhao J, Wang S, Markison S, et al. Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist. ACS Med Chem Lett 2023. 14 66–74. ( 10.1021/acsmedchemlett.2c00431) PubMed DOI PMC

Gadelha MR, Casagrande A, Strasburger CJ, et al. Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. J Clin Endocrinol Metab 2024. 110 228–237. ( 10.1210/clinem/dgae385) PubMed DOI PMC

Biller BM, Casagrande A, Elenkova A, et al. 12535 Efficacy and safety of once-daily oral paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled Pathfndr-2 study. J Endocr Soc 2024. 8 (Supp. 1) bvae163.1201. ( 10.1210/jendso/bvae163.1201) DOI

Chauhan A, Mohamed A, Usiskin K, et al. Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: results from a phase 2, randomized, parallel-group study. Endocr Abstr 2024. 108 C5. ( 10.1530/endoabs.108.C5) DOI

Kim R, Usiskin K, Fan X, et al. CAREFNDR: a phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours. In 22nd Annual ENETS Conference 2025. Berlin, Germany: ENETS, 2025. abstract #4663. (https://www.enets.org/abstract/carefndr-a-phase-iii-randomised-parallel-group-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-paltusotine-in-adults-with-carcinoid-syndrome-due-to-well-differentiated-neuroendocrine-tumours.html)

Aristizabal Prada ET, Orth M, Nolting S, et al. The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells. PLoS One 2017. 12 e0178375. ( 10.1371/journal.pone.0178375) PubMed DOI PMC

Pellegrino C, Favalli N, Volta L, et al. Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors. OncoImmunology 2024. 13 2412371. ( 10.1080/2162402x.2024.2412371) PubMed DOI PMC

Auernhammer CJ, Zitzmann K, Lindner S, et al. Upregulation of SSTR2 expression and radioligand binding of [ PubMed DOI PMC

Wang K, Schober L, Fischer A, et al. Opposing effects of cannabidiol in patient-derived neuroendocrine tumor, pheochromocytoma/paraganglioma primary cultures. J Clin Endocrinol Metab 2024. 109 2892–2904. ( 10.1210/clinem/dgae241) PubMed DOI PMC

Madan A, Markison S, Betz SF, et al. Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary 2022. 25 328–339. ( 10.1007/s11102-021-01201-z) PubMed DOI PMC

Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012. 97 2362–2369. ( 10.1210/jc.2012-1179) PubMed DOI

Fankhauser M, Bechmann N, Lauseker M, et al. Synergistic highly potent targeted drug combinations in different pheochromocytoma models including human tumor cultures. Endocrinology 2019. 160 2600–2617. ( 10.1210/en.2019-00410) PubMed DOI PMC

Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002. 146 707–716. ( 10.1530/eje.0.1460707) PubMed DOI

Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005. 45 836–844. ( 10.1177/0091270005277936) PubMed DOI

Veerman C, Siebinga H, de Vries-Huizing DMV, et al. The effect of long-acting somatostatin analogues on the uptake of [(177)Lu]Lu-HA-DOTATATE. Eur J Nucl Med Mol Imaging 2023. 50 1434–1441. ( 10.1007/s00259-022-06094-z) PubMed DOI

Wang R, Guo L & Shen G. Letter to the editor regarding “the effect of long-acting somatostatin analogs on the uptake of [(177)Lu]Lu-HA-DOTATATE”. Eur J Nucl Med Mol Imaging 2023. 51 180–182. ( 10.1007/s00259-023-06375-1) PubMed DOI

Yordanova A, Wicharz MM, Mayer K, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy. Clin Cancer Res 2018. 24 4672–4679. ( 10.1158/1078-0432.ccr-18-0947) PubMed DOI

Prasad V, Srirajaskanthan R, Toumpanakis C, et al. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice. Eur J Nucl Med Mol Imaging 2020. 47 2358–2371. ( 10.1007/s00259-020-04712-2) PubMed DOI PMC

Strosberg JR, Caplin ME, Kunz PL, et al. (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021. 22 1752–1763. ( 10.1016/s1470-2045(21)00572-6) PubMed DOI

Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017. 376 125–135. ( 10.1056/nejmoa1607427) PubMed DOI PMC

Lodge MA, Solnes LB, Chaudhry MA, et al. Prospective within-patient assessment of the impact of an unlabeled octreotide pre-dose on the biodistribution and tumor uptake of (68)Ga DOTATOC as assessed by dynamic whole-body PET in patients with neuroendocrine tumors: implications for diagnosis and therapy. Mol Imaging Biol 2021. 23 766–774. ( 10.1007/s11307-021-01600-5) PubMed DOI

Eschbach RS, Hofmann M, Spath L, et al. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE. Front Oncol 2023. 13 992316. ( 10.3389/fonc.2023.992316) PubMed DOI PMC

Haug AR, Rominger A, Mustafa M, et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011. 52 1679–1683. ( 10.2967/jnumed.111.089276) PubMed DOI

Wildemberg LE, Fialho C & Gadelha MR. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine. Best Pract Res Clin Endocrinol Metab 2024. 38 101906. ( 10.1016/j.beem.2024.101906) PubMed DOI

Zhao J, Fu H, Yu J, et al. Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine. Nat Commun 2023. 14 962. ( 10.1038/s41467-023-36673-z) PubMed DOI PMC

Campana C, Iyer AM, Ferone D, et al. Somatostatin receptors and the associated intracellular machinery: the two sides of the coin. J Endocrinol 2024. 260 e230298. ( 10.1530/joe-23-0298) PubMed DOI

Uygur MM, Villanova M, Frara S, et al. Clinical pharmacology of oral octreotide capsules for the treatment of acromegaly. Touchrev Endocrinol 2024. 20 37–42. ( 10.17925/ee.2024.20.1.9) PubMed DOI PMC

Strasburger CJ, Karavitaki N, Stormann S, et al. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol 2016. 174 355–362. ( 10.1530/eje-15-1042) PubMed DOI PMC

Exner S, Prasad V, Wiedenmann B, et al. Octreotide does not inhibit proliferation in five neuroendocrine tumor cell lines. Front Endocrinol 2018. 9 146. ( 10.3389/fendo.2018.00146) PubMed DOI PMC

Herrera-Martinez AD, van den Dungen R, Dogan-Oruc F, et al. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. Endocr Relat Cancer 2019. 26 585–599. ( 10.1530/erc-19-0086) PubMed DOI

Wang K, Schutze I, Gulde S, et al. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocr Relat Cancer 2022. 29 285–306. ( 10.1530/erc-21-0355) PubMed DOI

Wang K, Fischer A, Maccio U, et al. Impact of sex hormones on pheochromocytomas, paragangliomas, and gastroenteropancreatic neuroendocrine tumors. Eur J Endocrinol 2025. 192 46–60. ( 10.1093/ejendo/lvae163) PubMed DOI